Open AccessApalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study
Author(s) -
Neeraj Agarwal,
Kelly McQuarrie,
Anders Bjartell,
Simon Chowdhury,
Andrea Juliana Gomes,
Byung Ha Chung,
Mustafa Özgüroğlu,
Álvaro Juárez Soto,
Axel S. Merseburger,
Hirotsugu Uemura,
Dingwei Ye,
Robert Given,
Ethan Basch,
Branko Miladinović,
Angela Lopez-Gitlitz,
Kim N.
Publication year - 2021
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000001841
Subject(s) - medicine , placebo , prostate cancer , brief pain inventory , hazard ratio , androgen deprivation therapy , proportional hazards model , confidence interval , oncology , cancer , physical therapy , chronic pain , alternative medicine , pathology
We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo, with continuous androgen deprivation therapy (ADT), in the phase 3, randomized, double-blind, placebo controlled TITAN trial (NCT02489318).